AFG
OBIO icon

ABLE Financial Group’s Orchestra BioMed OBIO Stock Holding History

ABLE Financial Group’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.8K Hold
13,402
– – 0.01% 221
2026
Q1 		$57K Hold
13,402
– – 0.01% 206
2025
Q4 		$55.6K Hold
13,402
– – 0.01% 210
2025
Q3 		$33.2K Hold
13,402
– – 0.01% 205
2025
Q2 		$35.9K Hold
13,402
– – 0.01% 204
2025
Q1 		$57.4K Hold
13,402
– – 0.02% 196
2024
Q4 		$53.6K Hold
13,402
– – 0.02% 192
2024
Q3 		$68.9K Buy
+13,402
New +$87.5K 0.02% 187

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

ABLE Financial Group's OBIO Position: Q2 2026 in Review

ABLE Financial Group held its Orchestra BioMed (OBIO) position steady in Q2 2026 at 13,402 shares worth $57.8K. The position accounts for 0.01% of the portfolio, ranked #221.

ABLE Financial Group first reported a position in OBIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $68.9K in Q3 2024. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • ABLE Financial Group held 13,402 shares of Orchestra BioMed worth $57.8K as of Q2 2026.
  • ABLE Financial Group left its Orchestra BioMed share count unchanged in Q2 2026.
  • Orchestra BioMed made up 0.01% of ABLE Financial Group's portfolio in Q2 2026, its #221 holding.
  • ABLE Financial Group first reported a position in Orchestra BioMed in Q3 2024 and has held it in 8 quarters since.
  • ABLE Financial Group's Orchestra BioMed position peaked at $68.9K in Q3 2024.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on ABLE Financial Group's 13F filing for Q2 2026, filed 22 Jul 2026.